MSI2 has recently been found to be over-expressed in many cancers, including hematologic malignancies [5–11], colorectal adenocarcinomas [12–14], lung [15], pancreatic cancers [16–18], and glioblastoma [19]. Here, MSI2 is linked to familial pancreatic carcinoma.